Skip to main content

Table 2 Temporal immune and urticaria profiles for Case 2

From: Sustained control of recalcitrant chronic spontaneous urticaria after initiation of inflammatory airway diseases treatment: two case reports

 

Year (after LAI diagnosis)

 
 

− 1.2

0.1

4

5.2

6.2

Cellular findings

     

 Eosinophils

100

200

100

300

 

Complement (mg/dL)

     

 C1Q

    

7.8 (0.9X)

 C3

    

203 (1.03X)

 C4

    

28 (0.5X)

Antibody findings

     

 IgE

 

258

 

2218

 

 Ȃ-Thyroglobulin

< 1

< 1

 

< 1

 

 Ȃ-Thyroid Peroxidase

0.22 ×

  

1 ×

 

 Ȃ-C1q

    

Negative

 Ȃ-IgεR1

 

50 CUI (5X)

   

 Ȃ-Igε

   

64 (328X)

 

 BAT

501 (27X)

    

 ANCA

    

Negative

 Ȃ-Myeloperoxidase

    

< 1

 Ȃ-Proteinase 3

    

< 1

  1. Ȃ is Antibody (Ab) against given self-protein. BAT is a Basophil activation test and was data obtained from another site prior to treatment. The high values of autoantibodies to immunoglobulin E (IgE), given in mg/ml, may reflect the treatment of Omalizumab, a humanized monoclonal antibody to IgE. The Ȃ-IgεR1 IgE receptor test was unavailable in 2022. Patients elected to stop inhaler treatment before year 4 and resumed treatment between Year 4 at Year 5.2. ANCA is Anti-neutrophilic cytoplasmic antibodies. X values are given as the test value divided by disease threshold values for the test for elevated results
Back to article page

Journal of Medical Case Reports

ISSN: 1752-1947